OCGN
Ocugen Inc
NASDAQ · Biotechnology
$1.33
+0.00 (+0.00%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.92M | 214.85M | 205.76M | 219.05M |
| Net Income | -65,413,732 | -16,849,465 | -19,542,916 | -21,937,521 |
| EPS | — | — | — | — |
| Profit Margin | -1,333.0% | -7.8% | -9.5% | -10.0% |
| Rev Growth | +366.3% | +3.8% | +8.3% | +19.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 107.23M | 133.66M | 136.59M | 175.58M |
| Total Equity | 110.82M | 321.72M | 302.90M | 309.38M |
| D/E Ratio | 0.97 | 0.42 | 0.45 | 0.57 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -63,020,147 | -26,350,714 | -23,624,019 | -24,403,723 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 | -11,832,953 |